Wednesday, 20 September 2017

Celastrol: A Spectrum of Treatment Opportunities in Chronic Diseases

Front Med (Lausanne). 2017 Jun 15;4:69. doi: 10.3389/fmed.2017.00069. eCollection 2017. Cascão R1, Fonseca JE1,2, Moita LF3. Author information 1 Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal. 2 Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, Lisbon Academic Medical Centre, Lisbon, Portugal. 3 Instituto Gulbenkian de Ciência, Oeiras, Portugal. Abstract The identification of new bioactive compounds derived from medicinal plants with significant therapeutic properties has attracted considerable interest in recent years. Such is the case of the Tripterygium wilfordii (TW), an herb used in Chinese medicine. Clinical trials performed so far using its root extracts have shown impressive therapeutic properties but also revealed substantial gastrointestinal side effects. The most promising bioactive compound obtained from TW is celastrol. During the last decade, an increasing number of studies were published highlighting the medicinal usefulness of celastrol in diverse clinical areas. Here we systematically review the mechanism of action and the therapeutic properties of celastrol in inflammatory diseases, namely, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel diseases, osteoarthritis and allergy, as well as in cancer, neurodegenerative disorders and other diseases, such as diabetes, obesity, atherosclerosis, and hearing loss. We will also focus in the toxicological profile and limitations of celastrol formulation, namely, solubility, bioavailability, and dosage issues that still limit its further clinical application and usefulness. KEYWORDS: cancer; celastrol; clinical trials; inflammation; neurodegenerative diseases; toxicity; treatment PMID: 28664158 PMCID: PMC5471334 DOI: 10.3389/fmed.2017.00069 Free PMC Article